Linked Life Data

16619183

Source:http://linkedlifedata.com/resource/pubmed/id/16619183

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2006-4-18
pubmed:abstractText
An ex vivo liver slice-culture method was used to develop a novel assay of pretherapy interferon-based suppression. To evaluate its clinical application, 45 consecutive patients with chronic hepatitis C were included. They underwent the ex vivo antiviral assay, followed by a 24-week course of therapy with peginterferon and ribavirin. A stepwise logistic regression model was used to estimate the relationship between sustained virological response and the presence of various clinicopathological parameters. The results indicated that the presence of an interferon-based suppression effect in the ex vivo assay (odds ratio [OR], 12.454 [95% confidence interval {CI}, 1.115-139.090]; P=.0405), clinically diagnosed liver cirrhosis (OR, 0.081 [95% CI, 0.011-0.584]; P=.0126), and the portal-inflammation score (OR, 4.220 [95% CI, 1.264-14.085]; P=.0192) were independent determinants of sustained virological response. In conclusion, this new assay serves as an independent predictor of sustained virological response in interferon-based antiviral therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0022-1899
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
193
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1365-70
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
A novel ex vivo assay of interferon-based suppression, to predict the outcome of antiviral therapy for hepatitis C.
pubmed:affiliation
Liver Research Unit, Chang Gung Medical Center, and Department of Surgery, Chang Gung Children's Hospital, Taipei, Taiwan. chauting@adm.cgmh.org.tw
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Evaluation Studies